I-Mab (IMAB)
| Market Cap | 108.73M |
| Revenue (ttm) | 3.90M |
| Net Income (ttm) | -206.73M |
| Shares Out | 79.95M |
| EPS (ttm) | -2.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300,488 |
| Open | 1.400 |
| Previous Close | 1.390 |
| Day's Range | 1.200 - 1.440 |
| 52-Week Range | 1.160 - 2.960 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 12.25 (+800.74%) |
| Earnings Date | Aug 15, 2024 |
About IMAB
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1... [Read more]
Analyst Forecast
According to 4 analysts, the average rating for IMAB stock is "Strong Buy." The 12-month stock price forecast is $12.25, which is an increase of 800.74% from the latest price.
News
I-Mab Announces Leadership Transitions
ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has app...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri...
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...
I-Mab to Participate at the Jefferies Global Healthcare Conference
ROCKVILLE, Md. , May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated...
I-MAB Filed 2023 Annual Report on Form 20-F
ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiat...
I-Mab Announces Closing of the Divestiture of Business Operations in China
ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of high...
I-Mab Reports Full Year 2023 Financial Results and Business Update
Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (...
Biotech firm I-Mab to divest China operations, shift focus to US
I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarke...
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncolog...
I-Mab Announces Participation at Jefferies and Piper Conferences in November
ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients a...
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio I-Mab has full development and commercializati...
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
ROCKVILLE, MD, U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patie...
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
ROCKVILLE, Md. and SHANGHAI, China , Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients ...
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not...
AbbVie terminates deal with I-Mab to develop cancer drug
China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.
I-Mab Announces Upcoming Participation at September Conferences
ROCKVILLE, Md. and SHANGHAI , Sept.
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
Significant progress made year-to-date on key clinical assets:‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023‐ Givastomig (Claudin 18.2 x 4-1BB bis...
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
ROCKVILLE, Md. and SHANGHAI , Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializati...
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
GAITHERSBURG, Md. and SHANGHAI , July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializ...
I-Mab Announces the Appointment of Raj Kannan as CEO
GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and c...
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells. - In newly diagnosed patients who were ...
I-MAB Filed 2022 Annual Report on Form 20-F
GAITHERSBURG, Md. and SHANGHAI , May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and co...
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
GAITHERSBURG, Md. and SHANGHAI , April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercial...
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's groundless damages claim of over $200 million re...